Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Richard Finney
    Senior Member
    • Feb 2009
    • 701

    #1

    U.S. Supreme Court : "Can't Patent Genes"

    The Supreme Court ruled Thursday that companies cannot patent parts of naturally-occurring human genes, a decision with the potential to profoundly affect the emerging and lucrative medical and biotechnology ...


    WASHINGTON (AP) -- The Supreme Court ruled Thursday that companies cannot patent parts of naturally-occurring human genes, a decision with the potential to profoundly affect the emerging and lucrative medical and biotechnology industries.
    The high court's unanimous judgment reverses three decades of patent awards by government officials.
  • BAMseek
    Senior Member
    • Apr 2011
    • 124

    #2
    It seems to me that for all practical purposes, the Myriad gene patents are upheld (wall street seems to agree with that too). Even though isolated DNA is not eligible for patents like it was before, the cDNA product that is created in the lab is still eligible for patents. So our genes are patent-free but we are blind to read them?

    Justin

    Comment

    • Richard Finney
      Senior Member
      • Feb 2009
      • 701

      #3
      Agreed.


      The Supreme Court this morning ruled that human DNA cannot be patented. On the surface it appears to be a blow to Myriad Genetics, which was holding patents on two isolated genes, known as BRCA1 and BRCA2, and was at the center of the case. The genes can help indicate whether a woman has a heightened risk of developing breast or ovarian cancer, and it was the company’s test based upon them that convinced the actress Angelina Jolie to recently undergo a double-mastectomy.

      But the ability to patent another type of DNA, known as cDNA, was upheld, and it’s this partial verdict that has Myriad shares up. The court said DNA molecules synthesized in a laboratory were eligible for patent protection.


      Dang. Myriad won. You can't patent genes but you can patent the cDNA of the genes. So any practical assay of of BRCA1 and BRCA2 are owned by Myriad? You need cDNA to assay it , right?

      Comment

      • sdriscoll
        I like code
        • Sep 2009
        • 436

        #4
        Only if you are going to try to make money off of it. Then you just have to negotiate licensing. It doesn't interfere with non-profit research. At least that's what I've learned from the patents office where I work.
        /* Shawn Driscoll, Gene Expression Laboratory, Pfaff
        Salk Institute for Biological Studies, La Jolla, CA, USA */

        Comment

        • rskr
          Senior Member
          • Oct 2010
          • 249

          #5
          Don't all human mrna tissue samples get converted to cDNA for sequencing? I guess the question is how novel is patenting a cDNA? It seems like just about every MicroArray or RNA-seq experiment could potentially generate BRCA1 inadvertently, I am pretty sure they were producing cDNA of BRCA1 before they applied for a patent. Unless the scope is narrowed to producing a BRCA1 cDNA for a specific purpose maybe gene replacement therapy for instance, then it doesn't make much sense.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
            by SEQadmin2




            NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
            Yesterday, 06:46 AM
          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-28-2026, 09:57 AM
          0 responses
          29 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-28-2026, 09:51 AM
          0 responses
          20 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          71 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          48 views
          0 reactions
          Last Post SEQadmin2  
          Working...